{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:32:56Z","timestamp":1793244776937,"version":"4.5.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The persistence of risk of venous thromboembolism (VTE) due to combined hormonal contraceptives (CHCs), after their cessation, is unknown but important to guide clinical practice. The objective of this prospective cohort study was to define the time until normalization of estrogen-related thrombotic biomarkers after CHC cessation. We enrolled women aged 18 to 50 years who had decided to stop their CHC, excluding those with a personal history of VTE, anticoagulation, or pregnancy. The study started before cessation of CHC, with 6 visits afterwards (at 1, 2, 4, 6, and 12 weeks after cessation). Primary outcomes were normalized sensitivity ratios to activated protein C (nAPCsr) and to thrombomodulin (nTMsr), with sex hormone\u2013binding globulin (SHBG) as a secondary end point. We also included control women without CHC. Among 66 CHC users, from baseline until 12 weeks, average levels of nAPCsr, nTMsr, and SHBG decreased from 4.11 (standard deviation [SD], 2.06), 2.53 (SD, 1.03), and 167 nmol\/L (SD, 103) to 1.27 (SD, 0.82), 1.11 (SD, 0.58), and 55.4 nmol\/L (SD, 26.7), respectively. On a relative scale, 85.8%, 81.3%, and 76.2% of the decrease from baseline until 12 weeks was achieved at 2 weeks and 86.7%, 85.5%, and 87.8% at 4 weeks after CHC cessation, respectively. Levels were not meaningfully modified throughout the study period among 28 control women. In conclusion, CHC cessation is followed by a rapid decrease in estrogen-related thrombotic biomarkers. Two to 4 weeks of cessation before planned major surgery or withdrawal of anticoagulants in patients with VTE appears sufficient for the majority of women. The trial is registered at www.clinicaltrials.gov as #NCT03949985.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023021717","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T20:14:35Z","timestamp":1699474475000},"page":"70-78","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Longitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptives"],"prefix":"10.1182","volume":"143","author":[{"given":"Justine","family":"Hugon-Rodin","sequence":"first","affiliation":[{"name":"1Division of Gynecology, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland"},{"name":"2Gynecology Department, Gynecological Endocrinology Unit, Hospital Saint Joseph, INSERM Unit\u00e9 Mixte de Recherche 1153, \u00c9quipe de Recherche en \u00c9pid\u00e9miologie Obst\u00e9tricale P\u00e9rinatale et P\u00e9diatrique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1546-0774","authenticated-orcid":false,"given":"Pierre","family":"Fontana","sequence":"additional","affiliation":[{"name":"3Division of Angiology and Hemostasis, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0998-853X","authenticated-orcid":false,"given":"Antoine","family":"Poncet","sequence":"additional","affiliation":[{"name":"4Center for Clinical Research, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8767-0039","authenticated-orcid":false,"given":"Isabelle","family":"Streuli","sequence":"additional","affiliation":[{"name":"1Division of Gynecology, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7910-933X","authenticated-orcid":false,"given":"Alessandro","family":"Casini","sequence":"additional","affiliation":[{"name":"3Division of Angiology and Hemostasis, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7032-9491","authenticated-orcid":false,"given":"Marc","family":"Blondon","sequence":"additional","affiliation":[{"name":"3Division of Angiology and Hemostasis, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2024010416271677000_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/humupd\/dmv023","article-title":"Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods","volume":"21","author":"Bahamondes","year":"2015","journal-title":"Hum Reprod Update"},{"key":"2024010416271677000_bib26","unstructured":"United Nations Statistics\n          . World Contraceptive Use 2022. Accessed 31 March 2023. https:\/\/www.un.org\/development\/desa\/pd\/data\/world-contraceptive-use."},{"issue":"718","key":"2024010416271677000_bib2","first-page":"2383","article-title":"Contraception and venous thromboembolism","volume":"16","author":"Blondon","year":"2020","journal-title":"Rev Med Suisse"},{"key":"2024010416271677000_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2017.03.013","article-title":"Oral contraception and menstrual bleeding during treatment of venous thromboembolism: expert opinion versus current practice: combined results of a systematic review, expert panel opinion and an international survey","volume":"153","author":"Klok","year":"2017","journal-title":"Thromb Res"},{"issue":"4 pt 2","key":"2024010416271677000_bib4","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0002-9378(87)80129-1","article-title":"Coagulation effects of oral contraception","volume":"157","author":"Bonnar","year":"1987","journal-title":"Am J Obstet Gynecol"},{"issue":"6771","key":"2024010416271677000_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/bmj.302.6771.269","article-title":"Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery","volume":"302","author":"Robinson","year":"1991","journal-title":"BMJ"},{"issue":"1","key":"2024010416271677000_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000004445","article-title":"Prevention of venous thromboembolism in gynecologic surgery: ACOG practice bulletin, number 232","volume":"138","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins\u2014Gynecology","year":"2021","journal-title":"Obstet Gynecol"},{"key":"2024010416271677000_bib7","unstructured":"FSRH Clinical Effectivement Unit\n          . FSRH Guideline: Combined Hormonal Contraception. The Faculty of Sexual & Reproductive Healthcare. January 2019 (amended October 2023). Accessed 24 November 2023. https:\/\/www.fsrh.org\/standards-and-guidance\/documents\/combined-hormonal-contraception\/."},{"issue":"1","key":"2024010416271677000_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDtt2100050","article-title":"Should combined hormonal contraception be stopped in the perioperative period?","volume":"1","author":"Takvorian","year":"2022","journal-title":"NEJM Evidence"},{"issue":"1","key":"2024010416271677000_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism","volume":"126","author":"Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"issue":"6","key":"2024010416271677000_bib10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1538-7836.2012.04720.x","article-title":"Sex\u00a0hormone-binding globulin as a marker for the\u00a0thrombotic risk of hormonal contraceptives","volume":"10","author":"Raps","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024010416271677000_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/1354750X.2016.1204010","article-title":"Sex hormone-binding globulin and thrombin generation in women using hormonal contraception","volume":"22","author":"Hugon-Rodin","year":"2017","journal-title":"Biomarkers"},{"issue":"5","key":"2024010416271677000_bib12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/jth.12172","article-title":"Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial","volume":"11","author":"Raps","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2024010416271677000_bib13","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/aogs.14428","article-title":"Combined oral contraceptives containing estradiol valerate vs ethinylestradiol on coagulation: a randomized clinical trial","volume":"101","author":"Haverinen","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"2024010416271677000_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1538-7836.2009.03711.x","article-title":"APC resistance: biological basis and acquired influences","volume":"8","author":"Castoldi","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2024010416271677000_bib15","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.thromres.2014.09.008","article-title":"Changes in haemostatic parameters during the menstrual cycle and subsequent use of drospirenone-containing oral contraceptives","volume":"134","author":"Tchaikovski","year":"2014","journal-title":"Thromb Res"},{"issue":"9195","key":"2024010416271677000_bib16","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(99)06092-4","article-title":"Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study","volume":"354","author":"Rosing","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"2024010416271677000_bib17","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.contraception.2017.01.001","article-title":"Endogenous thrombin potential changes during the first cycle of oral contraceptive use","volume":"95","author":"Westhoff","year":"2017","journal-title":"Contraception"},{"issue":"3","key":"2024010416271677000_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0010-7824(02)00476-6","article-title":"The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study","volume":"67","author":"Oral Contraceptive and Hemostasis Study Group","year":"2003","journal-title":"Contraception"},{"issue":"4","key":"2024010416271677000_bib19","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1161\/STROKEAHA.111.643072","article-title":"Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy","volume":"43","author":"Rossouw","year":"2012","journal-title":"Stroke"},{"issue":"3","key":"2024010416271677000_bib20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.arthro.2020.10.025","article-title":"Combined oral contraceptive use increases the risk of venous thromboembolism after knee arthroscopy and anterior cruciate ligament reconstruction: an analysis of 64,165 patients in the Truven Database","volume":"37","author":"Traven","year":"2021","journal-title":"Arthroscopy"},{"issue":"2","key":"2024010416271677000_bib21","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/j.asmr.2021.12.010","article-title":"Venous thromboembolism prophylaxis and hormonal contraceptive management practice patterns in the perioperative period for anterior cruciate ligament reconstruction","volume":"4","author":"Christian","year":"2022","journal-title":"Arthrosc Sports Med Rehabil"},{"key":"2024010416271677000_bib22","first-page":"1","author":"World Health Organization","year":"2015","edition":"Fifth Edition"},{"issue":"6","key":"2024010416271677000_bib23","first-page":"961","article-title":"Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET)","volume":"84","author":"H\u00f8ibraaten","year":"2000","journal-title":"Thromb Haemost"},{"issue":"5","key":"2024010416271677000_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/gme.0b013e3181f9f7c3","article-title":"Hormone therapy and recurrence of venous thromboembolism among postmenopausal women","volume":"18","author":"Oli\u00e9","year":"2011","journal-title":"Menopause"},{"issue":"16","key":"2024010416271677000_bib25","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood.2022017101","article-title":"Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism","volume":"140","author":"de Jong","year":"2022","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/1\/70\/2180086\/blood_bld-2023-021717-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/1\/70\/2180086\/blood_bld-2023-021717-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T16:27:40Z","timestamp":1704385660000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/1\/70\/498621\/Longitudinal-profile-of-estrogen-related"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021717","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}